Here's Why Bellus Health Is Jumping Higher Today
Shares of Bellus Health (NASDAQ: BLU), a clinical-stage biotechnology company, are soaring in response to positive clinical-trial data. Investors excited about the company's lead candidate BLU-5937 drove the stock 58.4% higher as of 10:30 a.m. ET on Monday.
Bellus Health's lead candidate is a potential first-in-class P2X3 inhibitor for the treatment of refractory chronic cough (RCC) and eczema-related itching. The biotech stock is up sharply today because 28 days of treatment with BLU-5937 led to a significant improvement to RCC patients' daily cough frequency during the phase 2 Soothe trial. Compared to patients in the placebo group, Soothe participants randomized to receive 50 mg of BLU-5937 twice a day reduced their cough frequency by 34.4%.
Source Fool.com